The progesterone receptor (PR) is a ligand-activated nuclear steroid hormone receptor that functions as a transcription factor regulating gene expression in hormone-responsive tissues, including the mammary gland. PR signaling is closely linked to estrogen receptor (ER) activity, and its expression commonly reflects estrogen-regulated transcriptional programs in luminal breast cancer biology.
In oncologic pathology, PR immunohistochemistry (IHC) is routinely performed alongside ER assessment in breast carcinoma. PR status provides important prognostic information and contributes to molecular characterization of tumors, although endocrine therapy decisions are primarily driven by ER expression and overall clinical context.
Biological and Pathology Context
- Member of the steroid hormone receptor superfamily acting as a ligand-dependent nuclear transcription factor.
- Expression is frequently associated with ER signaling pathways and luminal breast cancer phenotypes.
- Nuclear immunostaining reflects physiological receptor localization within tumor cell nuclei.
- PR positivity supports identification of a hormone-responsive phenotype but is not lineage-specific and should be interpreted within a broader immunohistochemical panel.
Diagnostic Utility in Breast and Gynecologic Pathology
- ER and PR testing by IHC is recommended in primary breast carcinoma as part of routine biomarker evaluation for prognostic assessment and therapeutic stratification.
- PR expression contributes to tumor characterization and provides contextual information regarding functional estrogen signaling.
- The prognostic value of PR has been reported in multiple studies, although its independent predictive role remains subject to ongoing clinical evaluation.
- Interpretation of PR staining should consider tumor subtype, histologic context, and correlation with additional biomarkers.
Key Features of Anti-Progesterone Receptor CE/IVD Antibodies (IHC)
- High analytical concordance has been reported among validated monoclonal antibody clones used for PR detection.
- Strong nuclear staining pattern consistent with receptor biology and diagnostic expectations.
- Robust and reproducible antigen–antibody interactions documented under optimized pre-analytical and analytical conditions.
- High sensitivity for detection of PR-positive breast carcinomas when validated protocols and scoring criteria are applied.
